August Opens With a Biotech IPO Wave — But SpaceX's Billion-Share Unlock Is the Real Liquidity Test

The August IPO calendar opens with four new issues — three biotechs and a California bank — but the signal worth watching is not on the calendar. It is the 911.5 million SpaceX shares set to exit lockup on August 6, two business days after the company reports its first quarterly earnings as a public company. That single unlock will more than double the tradable float of a stock that has already fallen roughly 45% from its post-IPO peak, and it arrives against a backdrop of contracting order book depth, a depleted Federal Reserve reverse-repo buffer, and a fractured 9-3 FOMC vote that left the policy rate unchanged at 3.50%–3.75%.^[1][2]

The IPO Calendar: Biotechs and a Bank

Four IPOs are scheduled for the week ahead, led by cardiovascular biotech Braveheart Bio (BRVE), which is raising $300 million at a $1.4 billion market cap. Its lead candidate, BHB-1893, is a next-generation oral cardiac myosin inhibitor licensed from China’s Hengrui Pharmaceuticals, targeting both obstructive and non-obstructive hypertrophic cardiomyopathy. Braveheart plans to initiate a global Phase 3 trial in obstructive HCM in the second half of 2026, followed by a Phase 3 trial in non-obstructive HCM in the first half of 2027.^[3]

Immune-system biotech Attovia Therapeutics (ATTO) plans to raise $200 million at a $649 million market cap, developing biologic therapies for immune-mediated diseases via its ATTOBODY platform. Its lead candidate, ATTO-1310, targets IL-31 for chronic pruritus and high-itch atopic dermatitis, with a Phase 2 trial planned for the first half of 2027.^[3]

Metabolic disorder biotech Vogenx (VOGX) plans to raise $75 million at a $173 million market cap. Its lead candidate, mizagliflozin, is an oral, selective SGLT1 inhibitor licensed from Kissei Pharmaceutical, with a Phase 2b trial in post-bariatric hypoglycemia expected to begin screening patients this year.^[3]

Rounding out the calendar is California-based River City Bank (RCBC), raising $136 million at a $703 million market cap. Founded in 1973, the commercial bank serves businesses and real estate investors across Northern California, with commercial real estate lending accounting for roughly 90% of its loan portfolio as of June 30, 2026.^[3]

The broader IPO market has outperformed the S&P 500 in 2026: the Renaissance IPO Index was up 14.8% year-to-date as of July 30, compared with 9.4% for the S&P 500. Top holdings of the IPO ETF include Astera Labs (ALAB) and CoreWeave (CRWV). The Renaissance International IPO Index was up 29.7% year-to-date, well ahead of the ACWX benchmark at 12.0%.^[3]

SpaceX: The Largest Lockup Overhang in IPO History

The scale of the SpaceX lockup release is unprecedented. The average IPO typically sells about 20% of its shares to the public. SpaceX floated roughly 5% — only 629 million shares were sold at its June 12 IPO at $135 per share, valuing the company at approximately $1.77 trillion. That leaves an extraordinarily large pool of locked-up stock: more than 6.4 billion shares could ultimately hit the market through a series of staggered expirations running through the first anniversary of the IPO in June 2027.^[1]

Renaissance Capital’s senior strategist Matthew Kennedy called it “the longest series of lock-up releases we’ve ever seen.”^[1]

The first expiration on August 6 unlocks approximately 911.5 million shares. The next release, around August 20, frees another 455.8 million shares. Further expirations follow in September and continue at intervals through the first anniversary. Most of these releases do not cover shares owned by CEO Elon Musk, certain top executives, and board members; Musk’s stake becomes eligible in early June 2027, though he has said he does not plan to sell.^[1]

Morningstar equity analyst Nicolas Owens believes most available shares will come to market, citing the low cost basis and long holding periods of pre-IPO investors. “We believe that most of the available shares will come to market, because the existing sellers have low cost basis and long holding periods,” he said.^[1]

The stock has already been volatile. After pricing at $135 and briefly trading above $225 in its first week, shares broke below the IPO price in mid-July and fell toward $111 — an all-time low and a loss of roughly 45% for anyone who bought at the peak. Owens suggests that the lockup overhang is already being priced in: “It’s conceivable that a good deal of the recent slump in SpaceX stock is precisely in anticipation of the dilution from the lockup.”^[1]

The Index-Fund Absorption Problem

As the float expands, SpaceX’s weight in cap-weighted index funds will increase — but not necessarily by enough to absorb the supply. Morningstar analyst Zachary Evens points to the Invesco QQQ Trust (QQQ), which held roughly 39.7 million SpaceX shares on July 22, worth $4.57 billion and constituting a 0.98% portfolio weight. When SpaceX’s float-adjusted market cap triples — as could happen by the end of September — the Nasdaq index would treat the stock as a $675 billion company, placing it between Walmart and Intel in the QQQ portfolio.^[1]

“Every lockup expiration is an opportunity for SpaceX to claim a greater share of cap-weighted index funds,” Evens said. But Owens is skeptical that passive buying will be enough: “Unless something changes the fundamental story or sentiment — like for the better — the supply from these lockups will outweigh demand even from index funds.”^[1]

Liquidity Backdrop: Thinning Depth Beneath Rising Volume

The SpaceX unlock arrives in a market where liquidity is already fragile. JPMorgan and Goldman Sachs data show institutional trading volumes hit $4.2 trillion weekly, yet average order book depths contracted 23% since the start of Q2 2026. Transaction counts climbed 18% year-over-year, but the liquidity supporting mega-cap flows is increasingly synthetic — electronic market makers, facing tighter margin requirements under post-2024 regulatory reforms, have narrowed spreads on the largest names while widening spreads 12–18 basis points on lower-quartile liquid names.^[4]

Institutional buying in the Magnificent 7 technology names now represents 28% of total US equity institutional flow volume — the highest concentration since the 2000 tech bubble peak. Bridgewater Associates’ risk analysis flagged this clustering as a potential tail-risk amplifier in its July market outlook.^[4]

At the macro level, the liquidity buffer is essentially gone. The Overnight Reverse Repurchase (ON RRP) facility has flatlined at approximately $0.001 billion, removing the market’s primary shock absorber for Treasury issuance. Institutional net liquidity sits at roughly $5.827 trillion. The Federal Reserve is now managing liquidity via Reserve Management Purchases of short-term Treasury bills to counteract the drain from the $910 billion Treasury General Account.^[2]

The Dispersion Trade Is Narrowing

Another quiet indicator is the dispersion trade, which has dominated options markets for weeks. The spread between single-stock implied volatility (VIXEQ) and index-level implied volatility (VIX) remains exceptionally wide, but it is beginning to narrow as more companies report earnings. Historically, when this spread compresses, correlation among stocks rises and the S&P 500 tends to underperform.^[5]

Single-stock volatility, measured by VIXEQ, fell sharply following Alphabet’s and Tesla’s earnings reports, and has considerable room to move lower as earnings season winds down. While lower single-stock volatility is normally constructive, the narrowing of the dispersion spread is a mechanical factor that has historically coincided with weaker index performance.^[5]

The CBOE SKEW Index, at 147.28, sits well above the 100–120 neutral zone, indicating institutional hedging desks are paying up for out-of-the-money downside put protection even as the spot VIX remains a seemingly benign 18.58. The VIX term structure is in contango, with front-month futures at 18.61, three-month at 20.51, and one-year at 23.76 — a pattern consistent with hedging demand that rises with the horizon.^[2]

The FOMC’s Fractured Vote

The July 29 FOMC meeting produced a 9-3 vote to hold the federal funds rate at 3.50%–3.75%, with three dissenters — Beth M. Hammack, Neel Kashkari, and Lorie K. Logan — all preferring a 25-basis-point hike. A three-dissent FOMC vote is a profound anomaly. The short end of the curve dropped 8–12 basis points in the immediate aftermath, while the long end shifted higher, steepening the 10-2 spread to +0.34 percentage points (10-year at 4.67%, 2-year at 4.33%).^[2]

An inverted yield curve is a warning; an un-inverting yield curve is the detonation. The 10-2 spread’s move into sustained positive territory is a late-cycle indicator that, filtered through a century of market history, has preceded periods of severe economic deceleration. Whether that pattern repeats this time is an open question, but the signal is worth watching.^[2]

Buybacks: The Counterweight

On the demand side, corporate buyback programs continue to provide a structural bid. Shell announced a new $3 billion buyback programme on July 30, covering an approximately three-month contract term. BASF will begin a €1.0 billion buyback in August 2026, part of a larger €4 billion program running through 2028. Vale launched a 100 million-share buyback program. London Stock Exchange Group announced a £700 million buyback. Vinci implemented a share purchase agreement running from August 3 through September 3.^[6]

These programs provide a steady, rules-based demand source. But they are concentrated in large-cap international names and do little to offset the supply pressure from IPO lockup releases in the specific stocks most exposed to that overhang.

The Pipeline Behind August

Looking past the current calendar, the AI-infrastructure IPO pipeline continues to build. Lambda, the GPU-cloud provider and CoreWeave rival, has hired Morgan Stanley, JPMorgan, and Citi for an IPO targeted in the second half of 2026. Sacra estimates Lambda hit $505 million in annualized revenue as of May 2025, up from $425 million at the end of 2024.^[7]

Seven lock-up periods are expiring in the week ahead alone, alongside the four scheduled IPOs.^[3] The cumulative effect of these releases — layered on top of the SpaceX staggered unlocks running through mid-2027 — means the supply side of the equity market is entering a period of unusual pressure.

What to Watch Next

• August 4 (estimated): SpaceX reports its first quarterly earnings as a public company. The results will set the tone heading into the August 6 lockup release. Any disappointment in revenue, profitability, or Starship development timelines could amplify selling pressure from unlocked shares.
• August 6: Approximately 911.5 million SpaceX shares become eligible for sale. The volume and price action in the first three trading days will signal how much supply actually hits the market versus how much is absorbed by index-fund rebalancing.
• August 20 (estimated): A second SpaceX lockup release frees approximately 455.8 million additional shares. The cumulative float could roughly triple by the end of September.
• T-bill settlement schedule: Roughly $120 billion of Treasury settlements over July 28–31 drained liquidity from the system. Additional bill issuance is expected through September, with the pace of the drain potentially diminishing but remaining substantial.^[5]
• Dispersion spread compression: Watch the gap between VIXEQ and VIX. If it narrows sharply post-earnings, rising stock correlation could put mechanical pressure on the S&P 500.
• SKEW index: A reading above 140 signals institutional demand for tail-risk protection. If it rises further while spot VIX stays low, the divergence between positioning and realized volatility is widening — a pattern that typically resolves in one direction.
• Lambda IPO timing: Any filing or updated timeline from Lambda would signal whether the AI-infrastructure IPO window remains open in the second half of 2026, or whether the SpaceX overhang and broader liquidity conditions are prompting issuers to wait.

The base case is that index funds absorb a meaningful portion of the SpaceX supply, buyback programs provide a partial counterweight, and the IPO market continues to function — albeit at a slower pace than the first half of 2026. The risk case is that the combination of thinning order book depth, a depleted ON RRP buffer, a narrowing dispersion trade, and the largest lockup release in IPO history creates a supply shock that the current market structure is not equipped to absorb without dislocation. The evidence does not yet require choosing one scenario over the other, but the indicators worth monitoring are accumulating.